Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.39 |
| ▸ | SRC | P12931 | 13/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963053 | 1.00 | ABL1 (0.39) | ABL1SRCNTRK1GCK | |
| SCHEMBL2035734 | 0.92 | ABL1 (0.37) | ABL1SRCNTRK1 | |
| SCHEMBL1961938 | 0.83 | GCK (0.51) | ABL1SRCGCK | |
| SCHEMBL1961939 | 0.83 | GCK (0.51) | ABL1SRCGCK | |
| SCHEMBL1963201 | 0.81 | GCK (0.44) | ABL1SRCGCK | |
| SCHEMBL1963924 | 0.78 | PTGS2 (0.40) | NTRK1GCK | |
| SCHEMBL1963925 | 0.78 | PTGS2 (0.40) | NTRK1GCK | |
| SCHEMBL1959089 | 0.75 | GCK (0.51) | ABL1SRCGCK | |
| SCHEMBL1959091 | 0.75 | GCK (0.51) | ABL1SRCGCK | |
| SCHEMBL1961001 | 0.73 | NOD2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | ABL1 2649/4885SRC 2578/4885NTRK1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.